Core Insights - The FDA has granted clearance for Compugen's investigational new drug application for COM503, leading to a $30 million milestone payment from Gilead [1][2] - Compugen plans to initiate a Phase 1 trial for COM503 in advanced solid tumors in Q4 2024 [1][2] Company Overview - Compugen Ltd. is a clinical-stage cancer immunotherapy company specializing in computational target discovery [5] - The company has two proprietary product candidates in Phase 1 development: COM701 and COM902, alongside COM503 [5] COM503 Details - COM503 is a high affinity anti-IL-18 binding protein antibody, which is being developed as a monotherapy and in combination with Gilead's anti-PD-1 antibody, zimberelimab [3][4] - The Phase 1 trial will assess the safety and tolerability of COM503 in participants with advanced or metastatic solid tumors globally [3] Partnership with Gilead - In 2023, Compugen and Gilead entered a license agreement granting Gilead exclusive rights to develop and commercialize anti-IL-18 binding protein antibodies, including COM503 [4] - Gilead provided an upfront payment of $60 million and will make additional milestone payments, with a total deal value of up to $848 million [4]

HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinicalstage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a case study on clinical dose selection for TIGIT monospecific and bispecific antibodies at the Antibody Industrial Symposium taking place June 20-21, 2024, Montpellier, France. About Compugen Company contact: Yv ...

A downtrend has been apparent in Compugen (CGEN) lately. While the stock has lost 10.3% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings ...

HOLON, Israel, May 30, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical- stage cancer immunotherapy company and a pioneer in computational target discovery, today announced it is entitled to receive a milestone payment from AstraZeneca (LSE/STO/Nasdaq: AZN) triggered by the dosing of the first patient in a Phase 3 trial evaluating rilvegostomig, AstraZeneca's PD-1/TIGIT bispecific antibody. The TIGIT component of rilvegostomig is derived from Compugen's clinical-stage anti-TIGIT an ...

Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript May 20, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of IR & Corporate Communications Anat Cohen-Dayag - President and CEO Alberto Sessa - CFO Eran Ophir - CSO Michelle Mahler - CMO Asthika Goonewardene - Truist Securities Daina Graybosch - Leerink Tony Butler - Rodman & Renshaw Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's First Quarter 2024 Results Conference Call. At this time, all participants are i ...

Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this drug developer would post earnings of $0.10 per share when it actually produced earnings of $0.11, delivering a surprise of 10%. Investors should be mindful of the fact that the outl ...

Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 + COM902 + pembrolizumab study in microsatellite stable colorectal cancer with liver metastases planned to be presented at ASCO 2024 annual meeting On track to submit IND for COM503 in the second half of 2024 with preparation for Phase 1 study well advanced Partner, AstraZeneca, progressed rilvegostomig into second Phase 3 trial in nonsquamous NSCLC; Comp ...

Core Insights - Compugen Ltd. has published a peer-reviewed paper on the immune checkpoint PVRIG, highlighting its expression on stem-like T cells in tumors and its potential role in enhancing immune infiltration in non-inflamed tumors [1][2] - The company has demonstrated that the triple blockade of PVRIG, TIGIT, and PD-1 pathways using its antibody COM701 shows durable clinical responses and a favorable safety profile in typically non-responsive indications [2] - Compugen is advancing its pipeline with two proprietary product candidates, COM701 and COM902, targeting PVRIG and TIGIT respectively, and has a partnered program in Phase 3 development with AstraZeneca [3] Company Overview - Compugen is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapies, utilizing predictive computational discovery to identify new drug targets [3] - The company’s pipeline includes COM503, a potential first-in-class antibody in IND enabling studies, licensed to Gilead, which targets the interaction between IL-18 binding protein and IL-18 [3] - Compugen is headquartered in Israel and has offices in San Francisco, CA, with its shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]

Compugen Appoints David Silberman as Chief Financial Officer "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal addition to our team," said Anat Cohen-Dayag, Ph.D., President, and Chief Executive Officer of Compugen. "With experience in the healthcare industry as a Chief Financial Officer of a biotech company traded on the Nasdaq, along with his passion, strategic thinking and commitment for results, I look forward to working closely with David as part ...

HOLON, ISRAEL, May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2024 financial results on Monday, May 20, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial ...